Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal ...